Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is 5.65% higher on its value in year-to-date trading and has touched a low of $34.06 and a high of $60.37 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RARE stock was last observed hovering at around $52.18 in the last trading session, with the day’s loss setting it -1.66%.
Currently trading at $50.52, the stock is -6.36% and -8.72% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.58 million and changing -3.18% at the moment leaves the stock 5.33% off its SMA200. RARE registered 33.69% gain for a year compared to 6-month gain of 21.56%. The firm has a 50-day simple moving average (SMA 50) of $55.4862 and a 200-day simple moving average (SMA200) of $47.9344.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -5.22% loss in the last 1 month and extending the period to 3 months gives it a 0.46%, and is -2.55% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.31% over the week and 3.27% over the month.
Ultragenyx Pharmaceutical Inc (RARE) has around 1276 employees, a market worth around $4.66B and $522.75M in sales. Profit margin for the company is -106.93%. Distance from 52-week low is 48.33% and -16.32% from its 52-week high. The company has generated returns on investments over the last 12 months (-42.99%).
The EPS is expected to grow by 24.07% this year
404.0 institutions hold shares in Ultragenyx Pharmaceutical Inc (RARE), with institutional investors hold 103.54% of the company’s shares. The shares outstanding are 92.17M, and float is at 86.21M with Short Float at 3.67%. Institutions hold 99.78% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 9.78 million shares valued at $401.98 million. The investor’s holdings represent 11.6039 of the RARE Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.6 million shares valued at $230.3 million to account for 6.648 of the shares outstanding. The other top investors are SANDS CAPITAL MANAGEMENT, LLC which holds 5.35 million shares representing 6.353 and valued at over $220.08 million, while WELLINGTON MANAGEMENT GROUP LLP holds 5.4056 of the shares totaling 4.56 million with a market value of $187.26 million.
Ultragenyx Pharmaceutical Inc (RARE) Insider Activity
The most recent transaction is an insider sale by Horn Howard, the company’s Chief Financial Officer. SEC filings show that Horn Howard sold 7,465 shares of the company’s common stock on Oct 10 ’24 at a price of $52.76 per share for a total of $0.39 million. Following the sale, the insider now owns 92301.0 shares.
Ultragenyx Pharmaceutical Inc disclosed in a document filed with the SEC on Sep 03 ’24 that KAKKIS EMIL D (President & CEO) sold a total of 20,000 shares of the company’s common stock. The trade occurred on Sep 03 ’24 and was made at $55.85 per share for $1.12 million. Following the transaction, the insider now directly holds 2.22 million shares of the RARE stock.
Still, SEC filings show that on Sep 03 ’24, Huizenga Theodore Alan (SVP, Chief Accounting Officer) disposed off 91 shares at an average price of $56.19 for $5113.0. The insider now directly holds 41,551 shares of Ultragenyx Pharmaceutical Inc (RARE).
